Abstract
Hypoparathyroidism results in impaired mineral homoeostasis, including hypocalcaemia and hyperphosphataemia. Treatment with high-dose oral calcium and active vitamin D does not provide adequate or consistent control of biochemical indices and can lead to serious long-term complications. We aimed to test the efficacy, safety, and tolerability of once-daily recombinant human parathyroid hormone 1-84 (rhPTH[1-84]) in adults with hypoparathyroidism.
| Original language | English |
|---|---|
| Pages (from-to) | 275-283 |
| Number of pages | 9 |
| Journal | The Lancet Diabetes & Endocrinology |
| Volume | 1 |
| Issue number | 4 |
| Early online date | 7 Oct 2013 |
| DOIs | |
| Publication status | Published - 1 Dec 2013 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver